Corbus Pharmaceuticals Holdings, Inc. 8-K

What Happened
Corbus Pharmaceuticals (CRBP) filed an 8‑K on May 26, 2026 announcing updated clinical data from its Phase 1/2 study of CRB‑701 (SYS6002), a next‑generation Nectin‑4 targeted antibody‑drug conjugate. The data (April 1, 2026 cut) cover a safety population of 317 patients and will be presented at ASCO 2026 (May 29–June 2). The company reported robust activity in second‑line (2L) oropharyngeal squamous cell carcinoma (OPSCC) and cervical cancer at the 2.7 mg/kg and 3.6 mg/kg dose levels, and said it is on track to start a registrational randomized trial (TEMPO‑1) in 2L OPSCC in summer 2026 after broad FDA alignment on trial design.

Key Details

• Data cut: April 1, 2026; overall safety population n=317. ASCO presentation scheduled for May 29–June 2, 2026.
• OPSCC (efficacy‑evaluable n=41): cORR 20.0% at 2.7 mg/kg (4/20) and 42.9% at 3.6 mg/kg (9/21); DCR 90.0% and 85.7%; median DoR 4.8 and 6.3 months; median PFS 4.2 and 5.6 months.
• Cervical cancer (efficacy‑evaluable n=70): cORR 18.4% at 2.7 mg/kg (7/38, 1 CR) and 34.4% at 3.6 mg/kg (11/32, 2 CRs); DCR 55.3% vs 75.0%; DoR 6.8 vs 8.0 months; PFS 2.8 vs 4.3 months.
• Safety: most common treatment‑related AEs included keratitis (49.2%), alopecia (25.6%) and fatigue (22.4%). Grade 3 AEs 19.2%, Grade 4 AEs 0.9%, no Grade 5s. Ocular AEs in 66.2% (Grade 3 in 12.6%, one Grade 4 0.3%); discontinuations due to ocular AEs 1.9%; overall drug‑related discontinuations 2.8%.
• Biomarkers: 57.3% of HNSCC patients were HPV+ (85.4% of OPSCC); 8 of 9 PRs in OPSCC were HPV+. Corbus reports higher Nectin‑4 in HPV+ HNSCC.
• Regulatory path: Broad FDA alignment on randomized controlled registrational trials (TEMPO‑1 in 2L OPSCC, n≈250, ORR primary for potential accelerated approval; similar plan for 2L cervical cancer).

Why It Matters
These results show proof of activity for CRB‑701 in two HPV‑associated, Nectin‑4–high tumor types and identify a dose (3.6 mg/kg) with higher response rates in OPSCC and cervical cancer. Safety signals—particularly ocular AEs—are notable but described as manageable with prophylaxis and dose adjustments, and discontinuations remain low. For investors, the planned registrational trials and FDA alignment are the key near‑term milestones: positive randomized results could support accelerated approval based on ORR and, ultimately, full approval based on overall survival.